Search by Drug Name or NDC

    NDC 00074-0038-07 Orilissa 150 mg/1 Details

    Orilissa 150 mg/1

    Orilissa is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AbbVie Inc.. The primary component is ELAGOLIX SODIUM.

    Product Information

    NDC 00074-0038
    Product ID 0074-0038_0c3c5812-03a4-4ff2-bc62-786488dc4cc4
    Associated GPIs 30090030100320
    GCN Sequence Number 078657
    GCN Sequence Number Description elagolix sodium TABLET 150 MG ORAL
    HIC3 P1N
    HIC3 Description LHRH(GNRH) ANTAGONIST,PITUITARY SUPPRESSANT AGENTS
    GCN 45026
    HICL Sequence Number 045108
    HICL Sequence Number Description ELAGOLIX SODIUM
    Brand/Generic Brand
    Proprietary Name Orilissa
    Proprietary Name Suffix n/a
    Non-Proprietary Name Elagolix
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form TABLET, FILM COATED
    Route ORAL
    Active Ingredient Strength 150
    Active Ingredient Units mg/1
    Substance Name ELAGOLIX SODIUM
    Labeler Name AbbVie Inc.
    Pharmaceutical Class Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Decreased GnRH Secretion [PE], Gonadotropin Releasing Hormone Receptor Antagonist [EPC], Gonadotropin Releasing Hormone Receptor Antagonists [MoA], P-Glycoprotein Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA210450
    Listing Certified Through 2024-12-31

    Package

    NDC 00074-0038-07 (00074003807)

    NDC Package Code 0074-0038-07
    Billing NDC 00074003807
    Package 1 BLISTER PACK in 1 CARTON (0074-0038-07) / 7 TABLET, FILM COATED in 1 BLISTER PACK
    Marketing Start Date 2018-07-23
    NDC Exclude Flag N
    Pricing Information N/A